##  [Performance Evaluation of Companion Diagnostics](/white-papers/performance-evaluation-of-companion-diagnostics) 

- [Medical Devices](/white-papers-categories/medical-devices)
- [Clinical & Performance Evaluation](/white-papers-categories/clinical-performance-evaluation)





 ![Performance Evaluation of Companion Diagnostics]()

The **companion diagnostics (CDx)** market has become a cornerstone in the advancement of personalized medicine, offering critical support for targeted therapies and improving treatment outcomes. As Regulatory bodies heighten their focus on the safety, effectiveness, and clinical integration of CDx, performance evaluation has emerged as a vital requirement for manufacturers across the globe.

This whitepaper provides an **in-depth exploration** of the **Regulatory frameworks** governing the performance evaluation of companion diagnostics in both the **United States** and the **European Union**. It discusses key components such as scientific validity, analytical and clinical performance, lifecycle management requirements like Post-Market Performance Follow-up (PMPF), and the critical role of Regulatory coordination with the FDA, EMA, and Notified Bodies.

By understanding these evolving expectations, manufacturers can streamline their Regulatory submissions, ensure clinical reliability, and contribute effectively to the expanding landscape of precision healthcare.



Fill the form below to download the White Paper

 You must have JavaScript enabled to use this form.

  

  

  

 How did you hear about us?Search EngineE-mail CampaignGoogle AdsSocial MediaLink from another websiteColleague’s RecommendationNewsletterPrinted BrochureOther 

  

 

 

     I have read the [privacy policy](https://www.freyrsolutions.com/privacy-policy) 



 

 Submitted Page URL  

 Website URL  

 Content Type  

 Form Name